Evidence map›Paper›PMID 38075483›Full record

ArticleInternational journal of particle therapy2023

Strategic Operational Redesign Improves Prior Authorization Access: A Validation Study.

Eric D Brooks, Fantine Giap, Vincent Cassidy, Matthew S Ning, Bradlee Robbert, Polly Redding, Matthew Palmer, L Montreal Turner, William M Mendenhall, Stuart Klein and 1 more

Open access · diamondAbstract read
In one paragraph

Article in International journal of particle therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Revenue Cycle Management: The Art and the Science.Plastic and reconstructive surgery. Global open · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Eric D BrooksDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
Fantine GiapDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
Vincent CassidyDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
Matthew S NingDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bradlee RobbertUniversity of Florida Health Proton Therapy Institute, Jacksonville, FL, USA.
Polly ReddingUniversity of Florida Health Proton Therapy Institute, Jacksonville, FL, USA.
Matthew PalmerLegion Healthcare Partners, LLC, Houston, TX, USA.
L Montreal TurnerLegion Healthcare Partners, LLC, Houston, TX, USA.
William M MendenhallDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
Stuart KleinUniversity of Florida Health Proton Therapy Institute, Jacksonville, FL, USA.
Nancy P MendenhallDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA.
Florida College · USUniversity of Florida Health · USThe University of Texas MD Anderson Cancer Center · USUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Obtaining prior authorization (PA) before treatment is becoming increasingly burdensome in oncology, especially in radiation oncology. Here, we describe the impact of a strategic novel operational PA redesign to shorten authorization time and to improve patient access to cancer care at a large United States academic proton therapy center. We ask whether such a redesign may be replicable and adoptable across oncology centers. Materials and Methods: Our PA redesign strategy was based on a 3-tiered approach. Specifically, we (1) held payors accountable to legally backed timelines, (2) leveraged expertise on insurance policies and practices, and (3) updated the submission, appeal writing, and planning procedures for PA. Metrics were compared at the following 3 time points: 6 months before, at phase-in, and at 6 months after intervention. Results: In analyzing the impact of improving PA access to care, the percentage of approvals for commercial proton beam therapy improved by an absolute 30.6% postintervention ( Conclusion: This is the first validated, comprehensive operational strategy to improve access to cancer therapy while reducing the burden of PA. This novel approach may be helpful for addressing barriers to PA in medical and surgical oncology because the redesign is predicated on laws that regulate PA across disciplines.

Indexed as

approvalindependent review organizationprior authorizationprotonradiation

Identifiers

PMID38075483
PMCPMC10698628
OpenAlexW4386292843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.